JP2021531757A5 - - Google Patents
Info
- Publication number
- JP2021531757A5 JP2021531757A5 JP2021500916A JP2021500916A JP2021531757A5 JP 2021531757 A5 JP2021531757 A5 JP 2021531757A5 JP 2021500916 A JP2021500916 A JP 2021500916A JP 2021500916 A JP2021500916 A JP 2021500916A JP 2021531757 A5 JP2021531757 A5 JP 2021531757A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- monomer
- igg1
- domain monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696708P | 2018-07-11 | 2018-07-11 | |
| US62/696,708 | 2018-07-11 | ||
| PCT/US2019/041492 WO2020014545A1 (en) | 2018-07-11 | 2019-07-11 | Compositions and methods related to engineered fc-antigen binding domain constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531757A JP2021531757A (ja) | 2021-11-25 |
| JP2021531757A5 true JP2021531757A5 (enExample) | 2022-07-14 |
Family
ID=69141749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500916A Withdrawn JP2021531757A (ja) | 2018-07-11 | 2019-07-11 | 改変されたＦｃ−抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210238310A1 (enExample) |
| EP (1) | EP3820523A4 (enExample) |
| JP (1) | JP2021531757A (enExample) |
| KR (1) | KR20210043583A (enExample) |
| CN (1) | CN113164592A (enExample) |
| AU (1) | AU2019300020A1 (enExample) |
| BR (1) | BR112021000388A2 (enExample) |
| CA (1) | CA3106256A1 (enExample) |
| IL (1) | IL279999A (enExample) |
| MX (1) | MX2021000288A (enExample) |
| WO (1) | WO2020014545A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005879D0 (en) * | 2020-04-22 | 2020-06-03 | Petmedix Ltd | Heterodimeric proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902505A1 (en) * | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| WO2017151971A2 (en) * | 2016-03-02 | 2017-09-08 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
| CA3025310A1 (en) * | 2016-05-23 | 2017-11-30 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| AU2018205272A1 (en) * | 2017-01-06 | 2019-07-25 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs |
-
2019
- 2019-07-11 BR BR112021000388-6A patent/BR112021000388A2/pt not_active IP Right Cessation
- 2019-07-11 CN CN201980059596.3A patent/CN113164592A/zh active Pending
- 2019-07-11 KR KR1020217004259A patent/KR20210043583A/ko not_active Withdrawn
- 2019-07-11 AU AU2019300020A patent/AU2019300020A1/en not_active Abandoned
- 2019-07-11 JP JP2021500916A patent/JP2021531757A/ja not_active Withdrawn
- 2019-07-11 CA CA3106256A patent/CA3106256A1/en active Pending
- 2019-07-11 MX MX2021000288A patent/MX2021000288A/es unknown
- 2019-07-11 EP EP19835190.0A patent/EP3820523A4/en not_active Withdrawn
- 2019-07-11 WO PCT/US2019/041492 patent/WO2020014545A1/en not_active Ceased
- 2019-07-11 US US17/259,498 patent/US20210238310A1/en not_active Abandoned
-
2021
- 2021-01-07 IL IL279999A patent/IL279999A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551969A5 (enExample) | ||
| JP2024009962A5 (enExample) | ||
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| CN102448985B (zh) | 三或四特异性抗体 | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021094022A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2021520832A5 (enExample) | ||
| IL261674A (en) | Protein-like binding proteins with a double variable region have a cross-linking region direction | |
| JP2023545057A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2023548045A5 (enExample) | ||
| JP2023134618A5 (enExample) | ||
| JP2022545647A5 (enExample) | ||
| JP2023511376A5 (enExample) | ||
| JP2024501539A5 (enExample) | ||
| JP2022512234A5 (enExample) | ||
| JP7657591B2 (ja) | 二重特異性抗原結合コンストラクト | |
| JP2023548529A5 (enExample) | ||
| JP2025160226A5 (enExample) | ||
| JP2024512386A5 (enExample) | ||
| JP2021531268A5 (enExample) | ||
| JP2023549555A5 (enExample) | ||
| WO2018237341A1 (en) | A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY |